Poxel
Poxel is a research integrated pharmaceutical company that develops products for metabolic diseases.
Business Model:
Revenue: $2.2M
Employees: 51-200
Industries / Tags:
Detailed Poxel Information
Geographic Data
Address: 259-261 Avenue Jean Jaurès
City: Lyon
State: provence-alpes-côte-d'azur
Zip: 69007
Country: FR
Financial Info
Stage:
post ipo equity
Raised Last:
$6M
Raised Total:$109M
Social
Metrics
3,873,125Website Global Rank
3,334Website Monthly Traffic
Twitter Followers
Description
Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time. They believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).
Contact Phone:
Contact Email:
Poxel went public on 2/13/2015 on the PA
Listed Exchange:
PA
IPO Date:
2/13/2015
Ticker Symbol:
POXEL
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2010 | Series A | 4 | $21M |
Crédit Agricole Andera Partners Omnes Capital InnoBio Fund Crédit Agricole Andera Partners |
7/2015 | Post-IPO Equity | $22M | 8/2022 | Post-IPO Debt | 1 | - |
IPF Partners IPF Partners |
8/2022 | Post-IPO Equity | 1 | $6.1M |
IRIS Capital Investment IRIS Capital Investment |
2/2018 | Private Placement | $14.9M | 7/2016 | Post-IPO Equity | $29.3M | 2/2015 | IPO | $30.5M | 7/2015 | Private Placement | $32.3M | 6/2016 | Private Placement | $26.8M | 2/2015 | Private Placement | $4.1M | 12/2012 | Series B | 3 | $17.2M |
InnoBio Fund Omnes Capital Andera Partners InnoBio Fund Omnes Capital Andera Partners |
9/2014 | Series B | 3 | $13.5M |
Kreos Capital Andera Partners Bpifrance Kreos Capital Andera Partners Bpifrance |
8/2022 | Post-IPO Debt | 1 | - |
IPF Partners IPF Partners |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
